reports
Dime Community Bancshares Announces Closing of Common Stock Offering
Dime Community Bancshares Announces Closing of Common Stock Offering HAUPPAUGE, N.Y., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM) (“Dime” or the “Company”), the parent company of Dime Community Bank, announced the closing of its public offering of 4,492,187 shares of its common stock, $0.01 par value (the “Common Stock”), at a public offering price of $32.00 per share, which included 585,937 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. The total gross proceeds from the offeri...
Dime Community Bancshares Announces Pricing of Common Stock Offering
Dime Community Bancshares Announces Pricing of Common Stock Offering HAUPPAUGE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM) (“Dime” or the “Company”), the parent company of Dime Community Bank, announced the pricing of a public offering of 3,906,250 shares of its common stock, $0.01 par value (the “Common Stock”), at a public offering price of $32.00 per share, for aggregate gross proceeds of $125 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 585,937 shares of Common Stock at the p...
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipelin...
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2024, and provided recent pipeline and business updates. “We are pleased to be contin...
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovati...
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET ISELIN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that of Outlook Therapeutics will participate in a fireside chat on Tuesday, November ...
Dime Community Bancshares, Inc. Reports Third Quarter 2024 Results
Dime Community Bancshares, Inc. Reports Third Quarter 2024 Results Acceleration in Core Deposit Growth Drives Increase in Quarterly Net Interest Margin to 2.50% Balance Sheet Well Positioned to Benefit From Federal Reserve Rate Cuts HAUPPAUGE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), today reported net income available to common stockholders of $11.5 million for the quarter ended September 30, 2024, or $0.29 per diluted common share, compared to $16.7 million,...
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial...
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting BOTHELL, Wash., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD) will be presented at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) taking place Oct...
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect S...
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment ISELIN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CEO of Outlook Therapeutics participated in a segment. As part of this segment, Mr. Trenary provided an overview of the Company’s ...
Dime Community Bancshares to Release Earnings on October 22, 2024
Dime Community Bancshares to Release Earnings on October 22, 2024 HAUPPAUGE, N.Y., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the "Company") today announced that the Company expects to release its earnings for the quarter ended September 30, 2024 before the open of the U.S. equity markets on Tuesday, October 22, 2024. The Company will conduct a conference call at 9:00 a.m. (ET) on Tuesday, October 22, 2024, during which President and Chief Executive Officer (“CEO”), Stuart Lubow, will discuss the Company’s third quarter financial performance. There w...
Dime Community Bancshares Declares Quarterly Cash Dividend for Common ...
Dime Community Bancshares Declares Quarterly Cash Dividend for Common Stock HAUPPAUGE, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM) (the “Company”) announced that its Board of Directors declared a quarterly cash dividend of $0.25 per share of Common Stock, payable on October 24, 2024, to common stockholders of record as of October 17, 2024. The Company continues its trend of uninterrupted dividends. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a New York State-chartered tr...
Dime Enhances Middle Market Lending Presence on Long Island
Dime Enhances Middle Market Lending Presence on Long Island HAUPPAUGE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”) announced that it has hired Jason (“Jay”) Quinn as Senior Relationship Manager within its middle market C&I lending operations. Quinn was previously with Citibank for over twenty-six years, where he most recently served as Senior Vice President, Relationship Manager. He will be based in Melville and focused on growing Dime’s C&I business in Long Islan...
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of...
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025 Company announces cost containment measures in alignment with focus on advancing ATH-1105 BOTHELL, Wash., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused...
Outlook Therapeutics® to Participate in the Virtual Investor Closing B...
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ET ISELIN, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CE...
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual O...
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series ISELIN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that the Company recently participated in the 2nd Annual Chardan Virtual Ophthalmology Conference Series. Chardan’s 2nd Annual Virtual Ophthal...
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGH...
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial Topline results from NORSE EIGHT expected in Q4 CY2024 ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced the completion of enrollment for its NORSE EIGHT clinical trial evaluating ON...
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinica...
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In pre-specified subgroups of patients with moderate Alzheimer’s disease or who are APOE4 carriers, fosgonimeton showed a numerically greater treatment effect All biomarkers associated with Alzheimer’s disease pathology showed changes with fosgonimeton treatment consistent with the broad neuroprotective mechanism of HGF m...
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Gl...
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference ISELIN, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CEO of Outlook Therapeutics will present at the being held September 9-11, 2024 in New York, NY. In addition ...
Outlook Therapeutics® Reports Financial Results for Third Quarter Fisc...
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update Received European Union (EU) and United Kingdom (UK) Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMDNORSE EIGHT current enrollment pace supports topline readout target of Q4 CY2024Resubmission of the ONS-5010 Biologics License Application (BLA) on track for Q1 CY2025Quarterly update conference call and webcast today, Wednesday, August 14th at 8:30 AM ET ISELIN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: O...
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Oph...
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a fireside chat at the being held on Thursday, August 15, 2024. A of the fireside chat will be accessible for viewing on-demand beginning on Thursday, Augus...
Outlook Therapeutics® to Report Financial Results for Third Quarter Fi...
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet AMD, today announced that it will report its financial results for third quarter fiscal year 2024 on Wednesday, August 14, 2024. Outlook Therapeutics management will host i...
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeli...
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease targeted for September 2024 Phase 2/3 LIFT-AD data to be presented in an oral presentation at CTAD in October 2024 Phase 1 clinical trial of ATH-1105 underway for the potential treatment of amyotrophic lateral sclerosis (ALS) BOTHELL, Wash., Aug. 01, 2024 (G...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.